Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Arabidopsis thaliana leaf / E.coli / MEF proteomes label-free shotgun

ABSTRACT: Proteomic comparison of Arabidopsis thaliana leaf / E.coli / MEF proteomes generated by digestion with legumain, GluC and trypsin.

INSTRUMENT(S): maXis

ORGANISM(S): Escherichia Coli Arabidopsis Thaliana (mouse-ear Cress) Mus Musculus (mouse)

TISSUE(S): Cell Culture, Leaf

SUBMITTER: Fatih Demir

LAB HEAD: Pitter Florian Huesgen

PROVIDER: PXD014696 | Pride | 2020-01-20

REPOSITORIES: Pride

ACCESS DATA

Json Xml

Publications

ExteNDing Proteome Coverage with Legumain as a Highly Specific Digestion Protease.

Soh Wai Tuck WT Demir Fatih F Dall Elfriede E Perrar Andreas A Dahms Sven O SO Kuppusamy Maithreyan M Brandstetter Hans H Huesgen Pitter F PF

Analytical chemistry 20200131 4

Bottom-up mass spectrometry-based proteomics utilizes proteolytic enzymes with well characterized specificities to generate peptides amenable for identification by high-throughput tandem mass spectrometry. Trypsin, which cuts specifically after the basic residues lysine and arginine, is the predominant enzyme used for proteome digestion, although proteases with alternative specificities are required to detect sequences that are not accessible after tryptic digest. Here, we show that the human cy ...[more]

PMID: 31951383

Similar Datasets

Arabidopsis thaliana proteome label-free shotgun digested by Legumain in the presence of various denaturants

Project description:Proteomic optimisation of Arabidopsis thaliana proteome generated using legumain (cleave C-terminal of asparagine/aspartic acid) as protease in the presence of various concentration of denaturants such as acetonitrile, urea, and guanidinium-HCl.

2020-01-20 | PXD014699 | Pride

Arabidopsis thaliana leaf proteome label-free shotgun digested by Legumain at various pH

Project description:Proteomic optimisation of Arabidopsis thaliana leaf proteome generated using legumain (cleave C-terminal of asparagine/aspartic acid) as protease at different pH from pH 5.0 to pH 6.5.

2020-01-20 | PXD014698 | Pride

N-glycosylation site identification in Arabidopsis thaliana apoplastic fluid proteome

Project description:N-glycosylation site identification in Arabidopsis thaliana apoplastic fluid proteome by legumain using two alternative workflows to cross validate with dimethylation.

2020-01-20 | PXD014680 | Pride

HUNTER N-termini profiling of Arabidopsis thaliana leaves using different proteases

Project description:Comparison of protein N-termini in Arabidopsis thaliana leaves by the HUNTER method; the corresponding digestion was performed with legumain, GluC and trypsin.

2020-01-20 | PXD014697 | Pride

Arabidopsis chloroplast N-terminome

Project description:Protein N-termini are prone to post translational modification and are major determinants of protein stability in bacteria, eukaryotes, and perhaps also in chloroplasts. Most chloroplast proteins undergo N-terminal maturation, but this is poorly understood due to insufficient experimental information and the N-termini of mature chloroplast proteins cannot be accurately predicted. This motivated an extensive characterization of chloroplast protein N-termini using terminal amine isotopic labeling of substrates (TAILS). Many nuclear-encoded plastid proteins accumulated with two or three different N-termini; we evaluated the significance of these different proteoforms. Ala, Val, Thr (often in N-α acetylated form) and Ser were the most frequently observed N-terminal residues, even after normalization for their frequency in the plastid proteome, while other residues were absent or highly under-represented. Plastid-encoded proteins showed a similar distribution of N-terminal residues, but with a higher frequency of Met. Infrequent residues such as Ile, Arg, Cys, Pro, Asp and Glu were observed for several abundant proteins likely reflecting functional regulation through their N-termini. In contrast, the thylakoid lumenal proteome showed a wide diversity of N-terminal residues, including those typically associated with instability (Asp, Glu, Leu, Phe). We propose that after cleavage of the chloroplast transit peptide by stromal processing peptidase, additional processing by unidentified peptidases occurs to avoid unstable or otherwise unfavorable N-terminal residues. The possibility of a chloroplast N-end rule is discussed. This work provides a baseline for understanding N-terminal processing and maturation of chloroplast proteins.

2015-10-22 | PXD002476 | Pride

Genetic resistance elements carrying mef subclasses other than mef(A) in Streptococcus pyogenes.

Project description: Not available

| S-EPMC3122394 | biostudies-literature

In-depth and reproducibly quantitation of benchmark dataset consiting of 20 files

Project description:We prepared a benchmark dataset where the various levels of spikeed-in E. Coli proteome that true fold change (i.e. 1 fold, 1.5 fold, 2 fold, 2.5 fold and 3 fold) and true identities of positives/negatives (i.e. E.Coli proteins are true positives while Human proteins are true negatives) are known. To best mimic the proteomics application in comparison of multiple replicates, each fold change

2017-04-20 | PXD005590 | Pride

Identification of gastric cancer associated serum antibodies using Helicobacter pylori antigen microarrays

Project description:Unbiased de-novo identification of biomarkers for H.pylori associated gastric cancer; Microarrays, representing 242 seroreactive H.pylori proteins, were generated by spotting of the respective gene constructs and cell-free on-chip expression. Antibody levels to these proteins were measured by application of sera from non-cardia gastric cancer patients and their matched controls. Possible new biomarkers, associated with gastric cancer, were evaluated by unadjusted conditional regression.

2020-09-14 | E-MTAB-9534 | biostudies-arrayexpress

Murine CLPP protease substrate trapping in MEF cells

Project description:Classic susbtrate-trapping screen for ClpXP substrates using MEF cell lines overexpressing FLAG-tagged CLPP (WT), proteolytically inactive CLPP (TRAP) or vector control (NEG)

2020-06-01 | PXD015399 | Pride

Treatment effects of trastuzumab and TDM-1 in a murine model of breast cancer brain metastasis

Project description:Background: Central nervous system (CNS) metastases represent a major problem in the treatment of HER2-positive breast cancer due to the disappointing efficacy of HER2-targeted therapies in the brain microenvironment. The antibody-drug conjugate ado-trastuzumab emtansine (T-DM1) has shown efficacy in trastuzumab-resistant systemic breast cancer. Here, we tested the hypothesis that T-DM1 could overcome trastuzumab resistance in preclinical models of brain metastases. Methods: We treated mice bearing BT474 or MDA-MB-361 tumors in the CNS (N=9-11 per group), or cancer cells grown in organotypic brain slice cultures with trastuzumab or T-DM1 at equivalent or equipotent doses. Using intravital imaging, molecular techniques and histological analysis we determined tumor growth, mouse survival, cancer cell apoptosis and proliferation, tumor drug distribution, and HER2 signaling. All statistical tests were two-sided. Results: T-DM1 significantly delayed the growth of HER2-positive breast cancer brain metastases compared to trastuzumab. These findings were consistent between HER2-driven and PI3K-driven tumors. The activity of T-DM1 resulted in a striking survival benefit (median survival for BT474 tumors: 28d for trastuzumab vs 112d for T-DM1, HR=6.2, 95% CI=6.1 to 85.84; P<.001). No difference in drug distribution and HER2-signaling was revealed between the two groups. However, T-DM1 led to a significant increase in tumor cell apoptosis (One-way ANOVA for ApopTag, p<.001), which was associated with mitotic catastrophe. Conclusions: T-DM1 can overcome resistance to trastuzumab therapy in HER2-driven and PI3K-driven breast cancer brain lesions due to the cytotoxicity of the DM1 component. Clinical investigation of T-DM1 for patients with CNS metastases from HER2-positive breast cancer is warranted. Comparison of trastuzumab (n=4) and TDM-1 (n=4) treated BT-474 human breast carcinoma cells growing in murine brain

2015-11-09 | E-GEOD-69042 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data